Today’s Trademark – Arcellx

The trademark of ARCELLX is owned by Arcellx, Inc. and was registered in USTPO bearing
registration number 7300240 on February 6th, 2024.

Arcellx, Inc., established in December 2014, is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland. The company focuses on developing innovative cell
therapies for patients with cancer and other incurable diseases. Their lead product candidate, anitocabtagene autoleucel (anito-cel), is being developed for the treatment of relapsed or refractory multiple myeloma. Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.

Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective,
and more broadly accessible. They are reimagining cell therapy through the development of
innovative immunotherapies for patients with cancer and other incurable diseases.